Ranveer Singh's Jayeshbahi Jordaar was released in theatres and it failed to impress the audience. The film came out of the theatres within 2 weeks despite being based on a strong and important subject. While the film flopped at the box office, it has been receiving a lot of love on OTT. Along with Ranveer Singh, Boman Irani too played a prominent role in the film. The actor was seen as Ranveer's father and his performance was highly praised like always.
In an interaction with a news agency quoted by Indian Express Boman said that how we are in a state of flux and there are many variables to it. Citing the example of Jayeshbhai Jordaar as a classic example he added that it should have done better numbers, but it didn't work well at the box office. While the film received a lot of love on OTT release and are saying, this is such a nice film and are questioning why didn't it work. "Everything doesn’t have a tangible answer. Was it the marketing, was it the… I don’t know. William Goldman (American screenwriter) once famously said, ‘Nobody knows anything. If we knew, why isn’t every film a superhit?".
TRENDING NOW
Ranveer Singh's 83 too flopped at the box office
Well, we wonder if Ranveer's magic is slowly fading among the audience because his earlier release 83 helmed by Kabir Khan too wasn't a box office hit. The film was based on India's first world cup win in cricket and it was one of the most awaited films after the pandemic. However, the film was released during the Omicron threat and it is reported that this is the reason why Ranveer Singh starrer failed to attract an audience at the box office. Boman too was a part of this film.
Right now Ranveer is awaiting the release of his next film directed by Karan Johar who is backing his comeback as a filmmaker after Ae Dil Hai Mushkil - almost 6 years later. The film features Alia Bhatt as the leading lady. It also has Shabana Azmi and Dharmendra playing prominent roles. We hope this film manages to hit the right chord of the audience
Don’t Miss Out on the Latest Updates.
Subscribe to Our Newsletter Today!
Subscribe Now
Enroll for our free updates